Enliven Therapeutics, Inc./$ELVN
1D1W1MYTD1Y5YMAX
Capital at risk
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
- Ticker
- $ELVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 67
- Headquarters
- Boulder, United States
- Website
- www.enliventherapeutics.com
ELVN Metrics
BasicAdvanced
$4B
-
-$1.67
0.24
-
Price and volume
Market cap
$4B
Beta
0.24
52-week high
$62.32
52-week low
$14.79
Average daily volume
1M
Financial strength
Current ratio
64.073
Quick ratio
63.213
Long term debt to equity
0.001
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-124.284
Management effectiveness
Return on assets (TTM)
-11.00%
Return on equity (TTM)
-15.31%
Valuation
Price to book
4.45
Price to tangible book (TTM)
4.45
Price to free cash flow (TTM)
-51.452
Free cash flow yield (TTM)
-1.94%
Free cash flow per share (TTM)
-1.058
Growth
Earnings per share change (TTM)
-16.46%
3-year earnings per share growth (CAGR)
-18.72%
Bulls say / Bears say
ENABLE Phase 1b data show 61% overall major molecular response and 48% achieving MMR by 24 weeks at the 80 mg QD dose in refractory CML patients, demonstrating strong clinical activity for ELVN-001 (SEC)
Reached alignment with the FDA on key components of the ENABLE-2 Phase 3 2L+ trial design—confirming the 80 mg once-daily dose and second-line-and-beyond population—reducing regulatory risk for pivotal development (PRNewswire)
Closed an upsized public offering, raising approximately $460 million in gross proceeds, substantially strengthening the balance sheet to fund ELVN-001 pivotal trials into late-stage development (Investing.com)
Limited patient exposure and follow-up in the ENABLE Phase 1 trial—161 CML patients across dose levels as of March 10, 2026—may not adequately predict long-term safety and efficacy in broader populations (SEC)
Pipeline concentration risk persists as ELVN-002 remains in early Phase 1 monotherapy and combination cohorts while strategic alternatives are explored, limiting diversification beyond the CML program (Company Pipeline)
Enliven has never completed a clinical trial and has no approved products, heightening vulnerability to setbacks until ELVN-001’s Phase 3 readouts and regulatory approvals are achieved (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Upcoming events
No upcoming events
ELVN News
AllArticlesVideos
Funds containing ELVN
AllUSDGBPEUR
Fund name | Fund size | $ELVN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.23% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.23% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.06% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.